Design of future acute-stroke treatment trials
- 1 January 2003
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 2 (1) , 54-61
- https://doi.org/10.1016/s1474-4422(03)00267-9
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Trends in Acute Ischemic Stroke Trials Through the 20th CenturyStroke, 2001
- The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized TrialsJAMA, 2001
- The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and ElaborationAnnals of Internal Medicine, 2001
- Intravenous Ancrod for Treatment of Acute Ischemic StrokeJAMA, 2000
- Intra-arterial Prourokinase for Acute Ischemic StrokeJAMA, 1999
- CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic strokeThe Lancet, 1997
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic strokePublished by Elsevier ,1997
- Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic strokeThe Lancet, 1995